Cabozantinib (XL184) for the Treatment of Locally Advanced or Metastatic Progressive Medullary Thyroid Cancer

De Lellis RA LloydRV HeitzPU EngC. WHO Classification of Tumours. In: Pathology and Genetics of Tumours of Endocrine Organs. DeLellis RA (Ed.). ARC Press Lyon France 49–133 (2004).

10.1001/jama.295.18.2164

10.1089/thy.2008.0403

10.1007/s11864-004-0022-6

10.1016/S0025-6196(12)60923-9

10.1038/363458a0

10.1530/EJE-10-0333

10.1210/jc.2007-1005

10.1210/jc.2007-1714

10.1530/EJE-11-0079

10.1385/EP:11:1:19

10.1089/thy.2009.0417

Soh EY , DuhQY, SobhiSAet al. Vascular endothelial growth factor expression is higher in differentiated thyroid cancer than in normal or benign thyroid. J. Clin. Endocrinol. Metab. 82, 3741–3747 (1997).

10.1210/jc.2010-1921

10.1210/jc.2012-2092

10.1089/thy.2012.0207

10.1210/jc.2008-0923

10.1177/030089169007600513

10.1002/1097-0142(19851101)56:9<2155::AID-CNCR2820560903>3.0.CO;2-E

10.1200/JCO.2011.35.5040

10.1158/1535-7163.MCT-11-0264

10.1158/2159-8290.CD-11-0240

Schimmoller F , ZayzafoonM, Leland ChungLWKet al. Cabozantinib (XL184), a dual MET–VEGFR2 inhibitor, blocks osteoblastic and osteolytic progression of human prostate cancer xenografts in mouse bone. Mol. Cancer Ther. 10(11 Suppl. 1), Abstract A233 (2011).

Kurzrock R ShermanSI BallDWet al. Activity of XL184 (Cabozantinib) an oral tyrosine kinase inhibitor in patients with medullary thyroid cancer. J. Clin. Oncol. (19) 2660–2666 (2011).

Elisei R , MuellerS, SchoffskiPet al. Clinical and biochemical activity in the EXAM trial, a Phase III study of cabozantinib (XL184) in patients with hereditary and non-hereditary medullary thyroid carcinoma (MTC). Eur. Thyroid J. 1, Abstract OP1 (2012).

Schoffski P , EliseiR, MüllerSet al. An international double-blind, randomized, placebo-controlled Phase III (EXAM) of cabozantinib (XL184) in medullary thyroid cancer patients with documented RECIST progression at baseline. J. Clin. Oncol. 30(15 Suppl.), Abstract 5508 (2012).

Cohen E , EliseiR, SchlumbergerMet al. Clinical activity and pharmacokinetics (PK) of cabozantinib (XL184) in patients with medullary thyroid carcinoma (MTC). Ann. Oncol. 23(Suppl. 9), Abstract 1965 (2012).

10.1093/jnci/92.3.205

10.1200/JCO.2012.45.0494

10.1200/jco.2011.29.15_suppl.5008

10.1200/jco.2012.30.15_suppl.4007

10.1200/jco.2012.30.15_suppl.535

10.1200/jco.2012.30.15_suppl.8531

10.1200/jco.2012.30.15_suppl.7514

De Groot J , PradosM, UrquhartTet al. A Phase 2 study of XL184 in patients with progressive glioblastoma multiforme in first or second relapse. J. Clin. Oncol. 27(15 Suppl.), Abstract 2047 (2009).

10.1530/EJE-12-0828

10.1210/jc.2009-2507

10.1158/1078-0432.CCR-11-2700

10.1158/1078-0432.CCR-11-0933

10.1158/0008-5472.CAN-09-1077

Choueiri TK , PalSK, McDermottDFet al. Activity of cabozantinib (XL184) in patients (pts) with metastatic, refractory renal cell carcinoma (RCC). J. Clin. Oncol. 30(Suppl. 5), Abstract 364 (2012).

10.1200/jco.2012.30.15_suppl.5547

Wakelee HA , GettingerSN, EngelmanJAet al. A Phase Ib/II study of XL184 (BMS 907351) with and without erlotinib (E) in patients (pts) with non-small cell lung cancer (NSCLC). J. Clin. Oncol. 28(15 Suppl.), Abstract 3017 (2010).

National Cancer Institute. Thyroid cancer incidence (2012). www.cancer.gov/cancertopics/types/thyroid

US FDA. Oncologic Drugs Advisory Committee Meeting (2010). www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/OncologicDrugsAdvisoryCommittee/UCM236810.pdf

US FDA. Highlights of prescribing information (2012). www.accessdata.fda.gov/drugsatfda_docs/label/2012/203756lbl.pdf

ClinicalTrials.gov. Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100 (COMET-1). http://clinicaltrials.gov/show/NCT01605227

ClinicalTrials.gov. Study of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic Castration-resistant Prostate Cancer (COMET-2). http://clinicaltrials.gov/show/NCT01522443

National Cancer Institute. Surveillance epidemiology and end results 2005–2009. Case distribution by histology. http://seer.cancer.gov/csr/1975_2009_pops09/browse_csr.php?section=26&page=sect_26_table.22.html